Format

Send to

Choose Destination
Transfus Med. 2016 Feb;26(1):34-8. doi: 10.1111/tme.12271. Epub 2016 Jan 11.

Phenotyping Rh/Kell and risk of alloimmunization in haematological patients.

Author information

1
Serviço de Imunohemoterapia, Laboratório de Imuno-hematologia, Transfusion Medicine Department and Blood Bank, Centro Hospitalar São João.
2
Department of Haematology, São João University Hospital, Porto, Portugal.

Abstract

BACKGROUND:

One of the biggest concerns in transfusion medicine is to avoid red blood cell alloimmunization. We evaluated the rate of alloimmunization in two groups of chronically transfused patients (A - not phenotyped and B - phenotyped for Rh/K antigens before the first transfusion) with primary haematological disorders and its distribution among the main haematological diseases, in order to adopt an efficient transfusional strategy.

STUDY DESIGN AND METHODS:

As methodology, we used the SIBAS and SAM databases for the retrospective study of all patients with primary haematological disorder between January 2011 and April 2013.

RESULTS:

A statistical difference in the rate of alloimmunization comparing groups A and B was found (P <0·0001). We also observed that alloimmunization was not homogeneously distributed in all primary haematological diseases.

CONCLUSIONS:

The Rh/K phenotype should be performed on all patients diagnosed with bone marrow failure, plasma cell dyscrasia and myelodysplastic syndrome in order to avoid alloimmunization. In patients with acute leukaemia and lymphoma it seems not necessary to perform it. In patients with haemoglobinopathy and myeloproliferative disorders, a larger group of patients is needed to decide its efficacy.

KEYWORDS:

alloimmunization; cell transfusion; primary haematological disorder; red blood

PMID:
26751829
DOI:
10.1111/tme.12271
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center